Skip to main content
Top

Breast Cancer Research and Treatment

Issue 1/1999

Content (12 Articles)

Applying the Nottingham Prognostic Index to a Swedish breast cancer population

Marie Sundquist, Sten Thorstenson, Lars Brudin, Bo Nordenskjöld

Loss of heterozygosity in BRCA1 and BRCA2 markers and high‐grade malignancy in breast cancer

Jose M. Silva, Rocio Gonzalez, Mariano Provencio, Gema Dominguez, Jose M. Garcia, Isabel Gallego, Jose Palacios, Pilar España, Felix Bonilla

The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long‐term survival in Japanese patients with breast cancer

Takao Kato, Tsunehito Kimura, Nobue Ishii, Akiho Fujii, Kazuko Yamamoto, Shingo Kameoka, Toshio Nishikawa, Takeshi Kasajima

Antisense oligonucleotides to the epidermal growth factor receptor

Lois Witters, Rakesh Kumar, Mahitosh Mandal, C. Frank Bennett, Loren Miraglia, Allan Lipton

Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

A. Makris, T.J. Powles, D.C. Allred, S.E. Ashley, P.A. Trott, M.G. Ormerod, M. Dowsett

p53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaques

E. Isaksson, J.M. Cline, L. Skoog, G. Söderqvist, N. Wilking, E. von Schoultz, B. von Schoultz

Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro

Jian‐ming Xu, San‐tai Song, Zhong‐ming Tang, Ze‐fei Jiang, Xiao‐qing Liu, Li Zhou, Jing Zhang, Xiu‐wen Liu

Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome

Jeff Boyd, Esther Rhei, Mark G. Federici, Patrick I. Borgen, Patrice Watson, Barbara Franklin, Beth Karr, Jane Lynch, Stephen J. Lemon, Henry T. Lynch

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine